Truist Securities increased its price target for Medtronic plc (MDT) to $110 from $103, maintaining a Hold rating, following strong fiscal second-quarter revenue growth. The growth was primarily driven by the company's Pulsed Field Ablation (PFA) technology, which led to a 71% year-over-year organic rise in sales for the cardiac ablation solutions division. Despite a revenue beat, an operating margin miss and increased reinvestment limited upside growth and profit acceleration.

美敦力

<p>Truist Securities 将美敦力（Medtronic plc，股票代码：MDT）的目标股价从 103 美元上调至 110 美元，维持持有评级，此次调整是基于其强劲的财政第二季度收入增长。该增长主要得益于公司的脉冲场消融（PFA）技术，使心脏消融解决方案部门的销售同比增长了 71%。尽管收入超出预期，但运营利润率未达预期以及增加的再投资限制了上行增长和利润加速</p>

美敦力（MDT）目标价格被上调，因为 PFA 技术推动了第二季度的收入增长